ULTRESA CAPSULE (DELAYED RELEASE)

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

LIPASE; PROTEASE; AMYLASE

제공처:

APTALIS PHARMA CANADA ULC

ATC 코드:

A09AA02

INN (국제 이름):

MULTIENZYMES (LIPASE, PROTEASE ETC)

복용량:

13800UNIT; 53400UNIT; 58800UNIT

약제 형태:

CAPSULE (DELAYED RELEASE)

구성:

LIPASE 13800UNIT; PROTEASE 53400UNIT; AMYLASE 58800UNIT

관리 경로:

ORAL

패키지 단위:

100

처방전 유형:

Prescription

치료 영역:

DIGESTANTS

제품 요약:

Active ingredient group (AIG) number: 0302964034; AHFS:

승인 상태:

CANCELLED POST MARKET

승인 날짜:

2016-12-06

제품 특성 요약

_ _
_ULTRESA_
_®_
_ – Pancrelipase Capsules _
_ _
_ _
_ _
_ _
_ _
_ _
_Page 1 of 18 _
PRODUCT MONOGRAPH
PR
ULTRESA
®
(Pancrelipase USP)
Capsule (Delayed- Release)
13,800, 20,700 and 23,000 USP units of lipase
USP
Pancreatic enzymes
A09AA02
Aptalis Pharma Canada Inc.
597 Sir-Wilfrid-Laurier Blvd.
Mont-Saint-Hilaire, Québec
Canada J3H 6C4
Date of Approval:
June 05, 2015
Submission Control No: 173148
_ _
_ULTRESA_
_®_
_ – Pancrelipase Capsules _
_ _
_ _
_ _
_ _
_ _
_ _
_Page 2 of 18 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................8
DOSAGE AND ADMINISTRATION
................................................................................8
OVERDOSAGE
................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
............................................................10
STORAGE AND STABILITY
..........................................................................................11
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................11
PART II: SCIENTIFIC INFORMATION
...............................................................................13
PHARMACEUTICAL INFORMATION
..........................................................................13
CLINIC